This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00428/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/AHFS/
n17http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00428/identifier/kegg-drug/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00428/identifier/drugbank/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00428/identifier/national-drug-code-directory/
n16http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB00428/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00428/identifier/chebi/
n15http://www.rxlist.com/cgi/generic/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n9http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00428/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00428/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00428/identifier/pubchem-compound/
n27http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00428
rdf:type
n3:Drug
n3:description
An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals. [PubChem]
n3:dosage
n20:271B4C48-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# "Link":http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Streptozocin.htm # Brentjens R, Saltz L: Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am. 2001 Jun;81(3):527-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11459269 # Wang Z, Gleichmann H: GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes. 1998 Jan;47(1):50-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9421374 # Schnedl WJ, Ferber S, Johnson JH, Newgard CB: STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994 Nov;43(11):1326-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7926307 # VAVRA JJ, DEBOER C, DIETZ A, HANKA LJ, SOKOLSKI WT: Streptozotocin, a new antibacterial antibiotic. Antibiot Annu. 1959-1960;7:230-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13841501 # Mansford KR, Opie L: Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet. 1968 Mar 30;1(7544):670-1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4170654
n3:group
approved
n3:halfLife
5-15 minutes
n3:indication
For the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).
n3:manufacturer
n17:271B4C46-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00428 n16:DB00428
dcterms:title
Streptozocin
adms:identifier
n7:Streptozocin n12:PA451514 n19:46508872 n21:29327 n22:D05932 n23:0703-4636-01 n24:DB00428 n25:9288 n26:27273
n3:mechanismOfAction
Although its mechanism of action is not completely clear, streptozocin is known to inhibit DNA synthesis, interfere with biochemical reactions of NAD and NADH, and inhibit some enzymes involved in gluconeogenesis. Its activity appears to occur as a result of formation of methylcarbonium ions, which alkylate or bind with many intracellular molecular structures including nucleic acids. Its cytotoxic action is probably due to cross-linking of strands of DNA, resulting in inhibition of DNA synthesis.
n3:packager
n17:271B4C43-363D-11E5-9242-09173F13E4C5 n17:271B4C44-363D-11E5-9242-09173F13E4C5 n17:271B4C45-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
As much as 20% of the drug (or metabolites containing an N-nitrosourea group) is metabolized and/or excreted by the kidney.
n3:synonym
Estreptozocina 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose Streptozocin Streptozocinum Streptozotocin N-D-Glucosyl-(2)-n'-nitrosomethylharnstoff Zanosar Streptozocine N-D-Glucosyl-(2)-n'-nitrosomethylurea Streptozocinium
n3:toxicity
Symptoms of overdose include nausea and vomiting, anorexia, myelosuppression; and nephrotoxicity.
n13:hasAHFSCode
n14:10-00-00
foaf:page
n9:streptozocin.html n15:zanosar.htm
n3:IUPAC-Name
n4:271B4C4D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4C53-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4C52-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4C4F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4C50-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4C51-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4C63-363D-11E5-9242-09173F13E4C5 n4:271B4C4B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4C65-363D-11E5-9242-09173F13E4C5 n4:271B4C4C-363D-11E5-9242-09173F13E4C5 n4:271B4C49-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4C4A-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n27:L01AD04
n3:H-Bond-Acceptor-Count
n4:271B4C59-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4C5A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4C54-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4C55-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4C57-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4C56-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4C58-363D-11E5-9242-09173F13E4C5
n3:absorption
Poor oral absorption (17-25%)
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
18883-66-4
n3:category
n3:containedIn
n18:271B4C47-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4C5F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4C61-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4C62-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4C64-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4C5E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4C5D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4C60-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4C4E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4C5B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4C5C-363D-11E5-9242-09173F13E4C5